We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

600570:SSEHundsun Technologies Inc. Class A Analysis

Data as of 2026-03-17 - not real-time

CN¥27.56

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Hundsun Technologies is trading below its 20‑day SMA but above the 50‑day and 200‑day SMAs, indicating a short‑term pullback within a longer‑term downtrend. The RSI sits in the mid‑30s, suggesting modest oversold pressure, while the MACD line remains below its signal with a negative histogram, reinforcing bearish momentum. Price is hovering just above a clear support zone near 26.9 CNY and faces resistance around 31.1 CNY, limiting upside potential in the near term. Valuation metrics are starkly misaligned: the trailing P/E exceeds 50, well above the industry average of 34, and the DCF‑derived fair value is roughly one‑third of the current market price. Despite a solid cash position and low debt‑to‑equity, revenue growth is negative and margins, though healthy, are insufficient to justify the premium. Volatility remains elevated at over 27% on a 30‑day basis, yet beta is low, indicating the stock’s moves are more company‑specific than market‑driven. Dividend sustainability appears sound with a modest payout ratio, but the yield is negligible. Overall, the confluence of technical weakness, overvaluation, and deteriorating top‑line dynamics points to limited upside without a material catalyst.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD and RSI indicating downward pressure
  • Proximity to technical support with limited upside
  • Severe overvaluation relative to DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Negative revenue growth and high P/E versus peers
  • Strong cash balance providing a cushion
  • Persistent regulatory uncertainty in China’s fintech sector

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Long‑term secular demand for financial‑technology solutions
  • Robust balance sheet with low leverage
  • Regulatory risk and valuation gap may delay recovery

Key Metrics & Analysis

Financial Health

Revenue Growth-21.30%
Profit Margin17.90%
P/E Ratio50.1
ROE11.67%
ROA3.54%
Debt/Equity4.83
P/B Ratio5.8
Op. Cash FlowCN¥1.2B
Free Cash FlowCN¥987.1M
Industry P/E34.3

Technical Analysis

TrendBearish
RSI35.9
SupportCN¥26.92
ResistanceCN¥31.11
MA 20CN¥28.76
MA 50CN¥30.49
MA 200CN¥31.57
MACDBearish
VolumeStable
Fear & Greed Index81.64

Valuation

Fair ValueCN¥8.39
GradeOvervalued
TypeValue
Dividend Yield0.37%

Risk Assessment

Beta0.17
Volatility27.47%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.